Skip to main content
PMC home page
BioMed Research International logoLink to BioMed Research International
. 2020 Sep 7;2020:9175369. doi: 10.1155/2020/9175369

Corrigendum to “Peripheral Blood Mononuclear Cells as a Laboratory to Study Dementia in the Elderly”

Beatrice Arosio 1,2,✉, Claudio D'Addario 3,4, Cristina Gussago 2, Martina Casati 1, Enzo Tedone 2, Evelyn Ferri 2, Paola Nicolini 1, Paolo D Rossi 1, Mauro Maccarrone 5,6, Daniela Mari 1,2
PMCID: PMC7505014  PMID: 33005690

The article titled “Peripheral Blood Mononuclear Cells as a Laboratory to Study Dementia in the Elderly” [1] was found to contain a substantial amount of material from previously published articles including the following sources:

  1. Manraj S. Bhamra and Nicholas J. Ashton, “Finding a pathological diagnosis for Alzheimer's disease: Are inflammatory molecules the answer?: Proteomics and 2DE”, Electrophoresis, 2012. 10.1002/elps.201200161. [2] (not cited)

  2. Kelly M. Bakulski, Laura S. Rozek, Dana C. Dolinoy, Henry L. Paulson and Howard Hu, “Alzheimer's Disease and Environmental Exposure to Lead: The Epidemiologic Evidence and Potential Role of Epigenetics”, Current Alzheimer Research (2012) 9: 563. 10.2174/156720512800617991. [3] (cited as reference [75])

  3. Cristina Gussago, “Il Recettore Adenosinico A2a Come Possibile Biomarcatore Nella Diagnosi Differenziale Delle Demenze Nell'anziano”, Università Degli Studi Di Milano. 10.13130%2Fgussago-cristina_phd2014-03-10. [4] (not cited)

  4. B. Arosio, A. Bulbarelli, S. Bastias Candia, E. Lonati, L. Mastronardi, P. Romualdi, S. Candeletti, C. Gussago, D. Galimberti, E. Scarpini, B. Dell Osso, C. Altamura, M. Maccarrone, L. Bergamaschini, C. D Addario, D. Mari. “Pin1 Contribution to Alzheimer's Disease: Transcriptional and Epigenetic Mechanisms in Patients with Late-Onset Alzheimer s Disease”, Neurodegenerative Diseases, 2012.10.1159/000333799. [5] (cited as reference [66])

  5. K. Ando, P. Dourlen, A. V. Sambo et al., “Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker,” Neurobiology of Aging, vol. 34, no. 3, pp. 757–769, 2013. 10.1016/j.neurobiolaging.2012.08.004. [6] (cited as reference [69])

The authors apologise in particular for not acknowledging the work of Bhamra and Ashton (2012).

References

  • 1.Arosio B., D'Addario C., Gussago C., et al. Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. BioMed Research International. 2014;2014:14. doi: 10.1155/2014/169203.169203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bhamra M. S., Ashton N. J. Finding a pathological diagnosis for Alzheimer's disease: are inflammatory molecules the answer? Electrophoresis. 2012;33(24):3598–3607. doi: 10.1002/elps.201200161. [DOI] [PubMed] [Google Scholar]
  • 3.Bakulski K. M., Rozek L. S., Dolinoy D. C., Paulson H. L., Hu H. Alzheimer’s disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. Current Alzheimer Research. 2012;9(5):563–573. doi: 10.2174/156720512800617991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Gussago C. Il Recettore Adenosinico A2a Come Possibile Biomarcatore Nella Diagnosi Differenziale Delle Demenze Nell’anziano. UniversitàDegliStudi Di Milano; 2014. [Google Scholar]
  • 5.Arosio B., Bulbarelli A., Bastias Candia S., et al. Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimers disease. Neurodegenerative Diseases. 2012;10(1-4):207–211. doi: 10.1159/000333799. [DOI] [PubMed] [Google Scholar]
  • 6.Ando K., Dourlen P., Sambo A.-V., et al. Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiology of Aging. 2013;34(3):757–769. doi: 10.1016/j.neurobiolaging.2012.08.004. [DOI] [PubMed] [Google Scholar]

Articles from BioMed Research International are provided here courtesy of Wiley

RESOURCES